Literature DB >> 11923443

Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.

Deniz Kirik1, Carl Rosenblad, Corinna Burger, Cecilia Lundberg, Teit E Johansen, Nicholas Muzyczka, Ronald J Mandel, Anders Björklund.   

Abstract

Recombinant adeno-associated viral vectors display efficient tropism for transduction of the dopamine neurons of the substantia nigra. Taking advantage of this unique property of recombinant adeno-associated viral vectors, we expressed wild-type and A53T mutated human alpha-synuclein in the nigrostriatal dopamine neurons of adult rats for up to 6 months. Cellular and axonal pathology, including alpha-synuclein-positive cytoplasmic inclusions and swollen, dystrophic neurites similar to those seen in brains from patients with Parkinson's disease, developed progressively over time. These pathological alterations occurred preferentially in the nigral dopamine neurons and were not observed in other nondopaminergic neurons transduced by the same vectors. The degenerative changes were accompanied by a loss of 30-80% of the nigral dopamine neurons, a 40-50% reduction of striatal dopamine, and tyrosine hydroxylase levels that was fully developed by 8 weeks. Significant motor impairment developed in those animals in which dopamine neuron cell loss exceeded a critical threshold of 50-60%. At 6 months, signs of cell body and axonal pathology had subsided, suggesting that the surviving neurons had recovered from the initial insult, despite the fact that alpha-synuclein expression was maintained at a high level. These results show that nigral dopamine neurons are selectively vulnerable to high levels of either wild-type or mutant alpha-synuclein, pointing to a key role for alpha-synuclein in the pathogenesis of Parkinson's disease. Targeted overexpression of alpha-synuclein in the nigrostriatal system may provide a new animal model of Parkinson's disease that reproduces some of the cardinal pathological, neurochemical, and behavioral features of the human disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11923443      PMCID: PMC6758323          DOI: 20026246

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  45 in total

Review 1.  Pathoanatomy of Parkinson's disease.

Authors:  H Braak; E Braak
Journal:  J Neurol       Date:  2000-04       Impact factor: 4.849

2.  Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice.

Authors:  S Rathke-Hartlieb; P J Kahle; M Neumann; L Ozmen; S Haid; M Okochi; C Haass; J B Schulz
Journal:  J Neurochem       Date:  2001-05       Impact factor: 5.372

3.  alpha-synuclein promotes mitochondrial deficit and oxidative stress.

Authors:  L J Hsu; Y Sagara; A Arroyo; E Rockenstein; A Sisk; M Mallory; J Wong; T Takenouchi; M Hashimoto; E Masliah
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

4.  Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap.

Authors:  J E Conway; S Zolotukhin; N Muzyczka; G S Hayward; B J Byrne
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  The ubiquitin pathway in Parkinson's disease.

Authors:  E Leroy; R Boyer; G Auburger; B Leube; G Ulm; E Mezey; G Harta; M J Brownstein; S Jonnalagada; T Chernova; A Dehejia; C Lavedan; T Gasser; P J Steinbach; K D Wilkinson; M H Polymeropoulos
Journal:  Nature       Date:  1998-10-01       Impact factor: 49.962

6.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.

Authors:  R Krüger; W Kuhn; T Müller; D Woitalla; M Graeber; S Kösel; H Przuntek; J T Epplen; L Schöls; O Riess
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

Review 7.  Neuropathology of synuclein aggregates.

Authors:  J E Duda; V M Lee; J Q Trojanowski
Journal:  J Neurosci Res       Date:  2000-07-15       Impact factor: 4.164

8.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

9.  alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome.

Authors:  G K Tofaris; R Layfield; M G Spillantini
Journal:  FEBS Lett       Date:  2001-11-30       Impact factor: 4.124

10.  A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease.

Authors:  B I Giasson; R Jakes; M Goedert; J E Duda; S Leight; J Q Trojanowski; V M Lee
Journal:  J Neurosci Res       Date:  2000-02-15       Impact factor: 4.164

View more
  235 in total

Review 1.  Parkinson's disease: a rethink of rodent models.

Authors:  Heather L Melrose; Sarah J Lincoln; Glenn M Tyndall; Matthew J Farrer
Journal:  Exp Brain Res       Date:  2006-04-26       Impact factor: 1.972

Review 2.  Etiology of Parkinson's disease: Genetics and environment revisited.

Authors:  Kathy Steece-Collier; Eleonora Maries; Jeffrey H Kordower
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

3.  Attack on amyloid.

Authors:  Philipp J Kahle; Bart De Strooper
Journal:  EMBO Rep       Date:  2003-07-25       Impact factor: 8.807

Review 4.  Drug targets from genetics: α-synuclein.

Authors:  Karin M Danzer; Pamela J McLean
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

5.  BAX channel activity mediates lysosomal disruption linked to Parkinson disease.

Authors:  Jordi Bové; Marta Martínez-Vicente; Benjamin Dehay; Celine Perier; Ariadna Recasens; Agnes Bombrun; Bruno Antonsson; Miquel Vila
Journal:  Autophagy       Date:  2014-03-26       Impact factor: 16.016

6.  Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.

Authors:  Christophe Lo Bianco; Bernard L Schneider; Matthias Bauer; Ali Sajadi; Alexis Brice; Takeshi Iwatsubo; Patrick Aebischer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-02       Impact factor: 11.205

Review 7.  α-Synuclein nonhuman primate models of Parkinson's disease.

Authors:  David J Marmion; Jeffrey H Kordower
Journal:  J Neural Transm (Vienna)       Date:  2017-04-22       Impact factor: 3.575

Review 8.  Molecular mechanisms of alpha-synuclein neurodegeneration.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  Biochim Biophys Acta       Date:  2008-10-09

Review 9.  Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease.

Authors:  Masato Asanuma; Ikuko Miyazaki; Norio Ogawa
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

10.  Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy.

Authors:  Chee Yeun Chung; James B Koprich; Hasan Siddiqi; Ole Isacson
Journal:  J Neurosci       Date:  2009-03-18       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.